Opinion|Videos|November 25, 2024

Shared Decision-making for Selection of FDA-approved Therapies for NMOSD

Key Takeaways

  • Efficacy, safety, dosing frequency, and patient-specific factors are key in selecting NMOSD therapies.
  • Eculizumab and ravulizumab may be preferred for patients with severe relapses or contraindications to B-cell depletion.
SHOW MORE

A panelist discusses how when treating NMOSD, neurologists should consider the patient's clinical characteristics, safety profiles, administration requirements, and cost-effectiveness when selecting between FDA-approved therapies such as eculizumab, inebilizumab, satralizumab, ravulizumab, and rituximab. Shared decision-making is crucial, involving close collaboration between the healthcare team and the patient to develop a personalized treatment plan that considers the patient's overall well-being.

Episodes in this series

Video content above is prompted by the following:

  • What factors should be considered when choosing between other available FDA-approved therapies (eculizumab, inebilizumab, satralizumab, and ravulizumab) for patients with NMOSD?
  • What clinical characteristics can help guide neurologists in selecting eculizumab or ravulizumab versus rituximab?
  • Discuss shared decision-making when managing patients with APQ4+ NMOSD.

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Subscribe Now!

Related Content